For tumor KIT+ cell and macrophage analysis, tumors were minced, incubated in 12 mg/mL type 2 collagenase (Worthington Biochemical) plus 0.5 mg/mL DNAse I (Roche Diagnostics) for 30 minutes at 37°C, then washed through 100 then 40 μm nylon cell strainers (Falcon, BD Biosciences) with 1% fetal calf serum (FCS). For T cell analysis, tumors and draining lymph nodes (DLN) were mechanically dissociated as described (14 (link)). Spleens were mashed through a 70 μm strainer, incubated in ammonium chloride lysis buffer (eBioscience), quenched in 1% FCS, then washed through a 40 μm strainer. Bone marrow was flushed from one tibia per mouse, pooled by treatment group, homogenized by repeated aspiration through an 18-gauge needle, and then washed in 1% FCS. All cells were analyzed on a FACSAria (BD Biosciences) as described (14 (link)). Mouse-specific antibodies included CD45 (clone 30-F11), Kit (CD117) (2B8), CD11b (M1/70), CD3 (145-2C11), CD4 (GK1.5), Ly6C (AL-21), and Ly6G (1A8) from BD Biosciences; F4/80 (BM8) from Invitrogen; CD45 (30-F11), Kit (Ack2), CD8 (53–6.7), and FoxP3 (FJK-16s) from eBioscience. Intracellular staining for FoxP3 was performed using the FoxP3 Staining Buffer Set (eBioscience). Human-specific KIT antibody (YB5.B8) was purchased from BD Biosciences.